Harry Wilders

Harry Wilders


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGeorge S. Biggs
George S. Biggs
ECEmma E. Cawood
Emma E. Cawood
AVAini Vuorinen
Aini Vuorinen
WMWilliam J. McCarthy
William J. McCarthy
HWHarry Wilders
Harry Wilders
JBJacob T. Bush
Jacob T. Bush
Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ~23,000 cysteine sites per run, with a total of ~32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.

10 December 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
HWHarry Wilders
Harry Wilders
GBGeorge Biggs
George Biggs
SRSam M. Rowe
Sam M. Rowe
ECEmma E. Cawood
Emma E. Cawood
IRIoannis G. Riziotis
Ioannis G. Riziotis
JBJacob T. Bush
Jacob T. Bush
Reactive fragment (RF) screening has emerged as an efficient method for ligand discovery across the proteome, irrespective of a target's perceived tractability. To date, however, the efficiency of subsequent optimisation campaigns has largely been low‐throughput, constrained by the need for synthesis and purification of target compounds. We report an efficient platform for ‘direct‐to‐biology’ (D2B) screening of cysteine‐targeting chloroacetamide RFs, wherein synthesis is performed in 384‐well plates allowing direct assessment in downstream biological assays without purification. Here, the developed platform was used to optimise inhibitors of SARS‐CoV‐2 main protease (MPro), an established drug target for the treatment of COVID‐19. An initial RF hit was developed into a series of potent inhibitors, and further exploration using D2B screening enabled a ‘switch’ to a reversible inhibitor series. This example of ligand discovery for MPro illustrates the acceleration that D2B chemistry can offer for optimising RFs towards covalent inhibitor candidates, as well as providing future impetus to explore the evolution of RFs into non‐covalent ligands.

5 March 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
SRSam M. Rowe
Sam M. Rowe
APAlan Price
Alan Price
DMDennis J. Murphy
Dennis J. Murphy
JLJiarong Lin
Jiarong Lin
ENEldridge N. Nartey
Eldridge N. Nartey
JBJacob T. Bush
Jacob T. Bush
We report a ‘direct-to-biology’ (D2B) approach for optimising covalent acrylamide binders of protein targets and apply this to the identification of a selective and cell-active inhibitor of Werner (WRN) helicase. Inhibition of WRN helicase activity exhibits a synthetic lethal relationship with cancers displaying high microsatellite instability (MSI-H) and is being pursued as a therapeutic strategy in the clinic. Using intact-protein liquid chromatography-mass spectrometry (LC-MS) screening, we identified acrylamide fragment binders of the WRN helicase domain and then used covalent D2B chemistry to optimise these initial hits. Our efforts ultimately afforded a potent covalent inhibitor of WRN-mediated DNA unwinding, which displays selective, concentration-dependent cellular engagement of WRN, and demonstrates synthetic lethality in an MSI-H setting. Furthermore, our inhibitor targets a distinct conformation of WRN helicase compared to the current clinical covalent inhibitor, presenting a complementary approach for covalent inhibition of WRN helicase. This work demonstrates how D2B chemistry platforms can be used to explore structure-activity relationships in a modular fashion, while reducing investment of human and material resources.

10 December 2024 in Angewandte Chemie
Verified
Journal Article
Open access
HWHarry Wilders
Harry Wilders
GBGeorge Biggs
George Biggs
SRSam M. Rowe
Sam M. Rowe
ECEmma E. Cawood
Emma E. Cawood
IRIoannis G. Riziotis
Ioannis G. Riziotis
JBJacob T. Bush
Jacob T. Bush
Reactive fragment (RF) screening has emerged as an efficient method for ligand discovery across the proteome, irrespective of a target's perceived tractability. To date, however, the efficiency of subsequent optimisation campaigns has largely been low‐throughput, constrained by the need for synthesis and purification of target compounds. We report an efficient platform for ‘direct‐to‐biology’ (D2B) screening of cysteine‐targeting chloroacetamide RFs, wherein synthesis is performed in 384‐well plates allowing direct assessment in downstream biological assays without purification. Here, the developed platform was used to optimise inhibitors of SARS‐CoV‐2 main protease (MPro), an established drug target for the treatment of COVID‐19. An initial RF hit was developed into a series of potent inhibitors, and further exploration using D2B screening enabled a ‘switch’ to a reversible inhibitor series. This example of ligand discovery for MPro illustrates the acceleration that D2B chemistry can offer for optimising RFs towards covalent inhibitor candidates, as well as providing future impetus to explore the evolution of RFs into non‐covalent ligands.

25 July 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
JMJoseph Mason
Joseph Mason
HWHarry Wilders
Harry Wilders
DFDavid J. Fallon
David J. Fallon
RTRoss P. Thomas
Ross P. Thomas
JBJacob T. Bush
Jacob T. Bush
FRFrancesco Rianjongdee
Francesco Rianjongdee
High-throughput experimentation for chemistry and chemical biology has emerged as a highly impactful technology, particularly when applied to Direct-to-Biology. Analysis of the rich datasets which come from this mode of experimentation continues to be the rate-limiting step to reaction optimisation and the submission of compounds for biological assay. We present PyParse, an automated, accurate and accessible program for data extraction from high-throughput chemistry and provide real-life examples of situations in which PyParse can provide dramatic improvements in the speed and accuracy of analysing plate data. This software package has been made available through GitHub repository under an open-source Apache 2.0 licence, to facilitate the widespread adoption of high-throughput chemistry and enable the creation of standardised chemistry datasets for reaction prediction.

25 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GBGeorge S. Biggs
George S. Biggs
ECEmma E. Cawood
Emma E. Cawood
AVAini Vuorinen
Aini Vuorinen
WMWilliam J. McCarthy
William J. McCarthy
HWHarry Wilders
Harry Wilders
JBJacob T. Bush
Jacob T. Bush
Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ∼23,000 cysteine sites per run, with a total of ∼32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.